{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-180371","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2024-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.738346+00:00","generated_at":"2026-05-31T20:14:07.406359+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Atara Biotherapeutics' tab-cel BLA accepted for priority review by FDA; PDUFA Jan 15, 2025","bullets":["BLA for tabelecleucel (tab-cel) accepted for priority review to treat EBV+ PTLD in patients ≥2 years with ≥1 prior therapy.","PDUFA target action date set for January 15, 2025; no FDA-approved therapy currently exists for this indication.","BLA acceptance triggers $20M milestone payment from Pierre Fabre; up to $60M additional if FDA approves.","Supported by ALLELE study data showing 48.8% objective response rate (p<0.0001) and favorable safety profile.","Tab-cel already approved as Ebvallo in EU, UK, and Switzerland for relapsed/refractory EBV+ PTLD."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-180371","json":"https://secwatch.observer/filing/0001193125-24-180371.json","markdown":"https://secwatch.observer/filing/0001193125-24-180371.md","text":"https://secwatch.observer/filing/0001193125-24-180371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524180371/0001193125-24-180371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312524180371/d868530d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:14:07.406359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}